Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE:BTX opened at $6.83 on Friday. The firm has a market cap of $401.78 million, a PE ratio of -3.01 and a beta of 4.61. The firm’s 50 day simple moving average is $6.29 and its 200-day simple moving average is $3.19. Brooklyn ImmunoTherapeutics has a one year low of $5.10 and a one year high of $8.31.

Brooklyn ImmunoTherapeutics Dividend Announcement

The business also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were given a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a dividend yield of 15.14%. The ex-dividend date was Friday, March 14th. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is presently -45.37%.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.